In the world of pharmaceutical investing, few stories have been as closely watched—or as anxiety-inducing—as the patent expiration of AbbVie’s (ABBV) flagship drug, Humira. For years, Humira was the best-selling drug globally, a true blockbuster that formed the bedrock of AbbVie’s revenue. Now, with biosimilars eroding its market share, investors are rightly asking: what does the future hold, and what is a realistic price target for the stock?
The consensus among Wall Street analysts suggests a strong vote of confidence in AbbVie’s transition strategy, with an average price target hovering between $247 and $254 . This implies a significant upside from the current trading price of approximately $214 . To understand this bullish outlook, we must look beyond the rearview mirror of Humira and focus on the powerful growth engines AbbVie has meticulously built.
The Successful Humira Transition: A New Immunology Powerhouse
The primary risk to AbbVie, often referred to as the “patent cliff,” was the loss of exclusivity (LOE) for Humira. The company has already absorbed a substantial impact, estimated at around $10 billion in erosion since the LOE . However, the key to the stock’s price target is the successful launch and ramp-up of its next-generation immunology drugs: Skyrizi (risankizumab) and Rinvoq (upadacitinib).
These two drugs are not just replacements; they are superior growth drivers. AbbVie’s management has consistently raised its guidance for these products, now projecting combined sales to exceed $27 billion by 2027 . This is a remarkable feat of commercial execution. For context, Skyrizi alone reported net revenues of $4.7 billion in the third quarter of 2025, representing a staggering 46% year-over-year growth . The global immunology market itself is a high-growth sector, projected to reach over $200 billion by 2033, providing a massive runway for these two blockbusters .
Financial Strength and Undervalued Growth
The success of Skyrizi and Rinvoq is directly translating into a dramatic shift in AbbVie’s financial profile, which is the core driver of the analyst price targets. The company is poised for a significant earnings rebound in 2026, which fundamentally changes its valuation picture.
| Financial Metric | 2025 Estimate | 2026 Estimate | Year-over-Year Change |
| Revenue | ~$60.94 Billion | ~$66.8 Billion | ~9.6% |
| Adjusted EPS | ~$10.37 | ~$14.25 | ~37.4% |
Source: Yahoo Finance Analyst Estimates
This projected jump in earnings per share (EPS) to over $14.00 in 2026 is the primary reason for the stock’s attractive valuation. Based on the current stock price, AbbVie trades at a Forward P/E ratio of approximately 15x to 16x . This is a substantial discount when compared to the S&P 500 average of around 22x and many of its pharmaceutical peers. In the eyes of many experts, this valuation gap suggests that the market has not yet fully priced in the company’s post-Humira growth trajectory.
Furthermore, AbbVie remains a favorite for income investors. It is a Dividend Aristocrat, having consistently increased its dividend for decades. With a current dividend yield of approximately 3.1% and a forward payout ratio estimated at a sustainable 57% based on 2026 earnings, the stock offers both growth potential and a robust income stream .
Strategic Diversification: The Pipeline of Tomorrow
A sustainable price target requires more than just two successful drugs; it demands a deep and diversified pipeline. AbbVie has strategically used its financial strength to acquire future growth drivers, effectively de-risking its long-term outlook.
In 2024, AbbVie completed two major acquisitions:
1.ImmunoGen ($10.1 Billion): This acquisition brought the Antibody-Drug Conjugate (ADC) Elahere into its portfolio, significantly bolstering its oncology presence . The ADC market is one of the fastest-growing segments in cancer treatment, with a projected CAGR of nearly 29% . Elahere is a “smart bomb” therapy that targets cancer cells with high precision, positioning AbbVie at the cutting edge of oncology.
2.Cerevel Therapeutics ($8.7 Billion): This move was a major bet on neuroscience, adding a promising pipeline of treatments for conditions like schizophrenia and Parkinson’s disease . This diversification into a high-unmet-need area provides a new, multi-billion-dollar growth vector for the 2030s.
These strategic moves demonstrate a clear commitment to building a sustainable, multi-pillar revenue base that will support future price appreciation.
The Analyst Consensus and Price Target Breakdown
The analyst community’s price targets are a synthesis of these factors. The average target of $247-$254 is based on applying a slightly higher, but still conservative, P/E multiple (perhaps 17x-18x) to the expected 2026 EPS of $14.25.
| Price Target Range | Rationale |
| Low End (~$218) | Reflects a cautious view, assuming slower-than-expected uptake of Skyrizi/Rinvoq or greater-than-expected regulatory pressure from the Inflation Reduction Act (IRA) . |
| Average ($247 – $254) | Represents the consensus view: successful Humira transition, strong growth from immunology, and a fair valuation multiple applied to 2026 earnings. |
| High End (~$328) | Reflects a highly optimistic scenario where the market assigns a premium growth multiple (closer to 22x) to the 2026 earnings, recognizing the full potential of the ImmunoGen and Cerevel pipelines. |
Conclusion: A Clear Path to Revaluation
AbbVie’s stock price target is not a matter of hope; it is a calculation based on a successful strategic pivot. The company has navigated the Humira patent cliff with remarkable skill, replacing lost revenue with two powerful, growing blockbusters. The aggressive, yet prudent, acquisitions of ImmunoGen and Cerevel have laid the groundwork for sustainable growth well into the next decade.
For investors, the current price offers a compelling opportunity: a high-growth pharmaceutical stock trading at a value multiple. The consensus price target of $247-$254 is a realistic expectation, driven by the anticipated surge in 2026 earnings. AbbVie is no longer defined by its past; it is a diversified, high-growth, and undervalued pharmaceutical giant with a clear path to revaluation.